A prospective clinical study of concurrent chemoradiotherapy with nedaplatin for patients with middle-advanced stage uterine cervical carcinoma
10.3760/cma.j.issn.1673-422X.2014.06.022
- VernacularTitle:奈达铂同期放化疗治疗中晚期宫颈癌前瞻性临床研究
- Author:
Weijun YE
;
Min XU
;
Xinping CAO
;
Hua JIN
;
Hongying LIU
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Radiotherapy;
Drug therapy
- From:
Journal of International Oncology
2014;41(6):476-479
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin versus cisplatin for patients with middle-advanced stage uterine cervical carcinoma.Methods 180 patients with middle-advanced stage uterine cervical carcinoma were randomized into concurrent chemoradiotherapy with nedaplatin group (nedaplatin group) and concurrent chemoradiotherapy with cisplatin group (cisplatin group).The short-term efficacy and the toxicity were observed.Results In the nedaplatin group,the short-term response rate、the one-year relapse-free surviva l、one-yea metastasis-free survival、the two-year relapse-free survival、the two-year metastasis-free survival were 98.85%、89.66、86.21% 、85.06% 和 80.46%,But in the cisplatin group,the short-term response rate 、the one-year relapse-free surviva l、one-yea metastasis-free survival、the twoyear relapse-free survival、the two-year metastasis-free survival were 97.60% (x2 =3.07,P > 0.05) 、81.93%(x2 =3.07,P >0.05) 、83.13% (x2 =0.31,P >0.05) 、78.31% (x2 =1.30,P >0.05) 和 80.72% (x2 =0.00,P > 0.05),so there was no significant difference.The incidences of nausea and vomiting in the cisplatin group were 52.27% (grade Ⅰ ~ Ⅳ toxicities),12.50% (grade Ⅲ ~ Ⅳ toxicities),which were higher than those in the nedaplatin group 27.27% (grade Ⅱ ~ Ⅳ toxicities),6.82% (grade Ⅲ ~ Ⅳ toxicities) (P < 0.05),while there were no significant difference in the other toxicities such as anemia,granulocytopenia,thrombocytopenia,diarrhoea between the two groups (x2 =12.18,P > 0.05).Conclusion The efficacy of concurrent chemoradiotherapy with nedaplatin is the same as that of concurrent chemoradiotherapy with cisplatin,and its toxicity is well-tolerated.